Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates (Q33406591)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase I clinical trial

0 references

0 references

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

R K Kelley

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

H S Nimeiri

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

P N Munster

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

M T Vergo

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Y Huang

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

C-M Li

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

J Hwang

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

M F Mulcahy

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

B M Yeh

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

P Kuhn

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

M S Luttgen

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

J A Grabowsky

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

L Stucky-Marshall

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

W M Korn

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A H Ko

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

E K Bergsland

16

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A B Benson

17

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A P Venook

18

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

21 March 2013

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1900-1907

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

Bacterial infections other than spontaneous bacterial peritonitis in cirrhosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

Activation of PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

Phase 1/2 study of everolimus in advanced hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

Two Drug Interaction Studies of Sirolimus in Combination with Sorafenib or Sunitinib in Patients with Advanced Malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

Management of hepatocellular carcinoma: An update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

Pivotal role of mTOR signaling in hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690907

28 July 2018

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT109

21 January 2018

The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT109

21 January 2018

Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT109

21 January 2018

Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT109

21 January 2018

ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT109

21 January 2018

Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT109

21 January 2018

Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT109

21 January 2018

PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT109

21 January 2018

Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT109

21 January 2018

A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT109

21 January 2018

Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT109

21 January 2018

Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT109

21 January 2018

Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT109

21 January 2018

Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT109

21 January 2018

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT109

21 January 2018

New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23519998

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: A meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23519998

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/ANNONC/MDT109

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33406591&oldid=2143324786"